NCT02967250View on ClinicalTrials.gov

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Parkinson Disease
Interventions
DRUG

ursodeoxycholic acid

Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.

Trial Locations (1)

55455

Center for Magnetic Resonance Research, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02967250 - Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment | Biotech Hunter | Biotech Hunter